Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity

1. A formulation comprising an HIV envelope glycoprotein polypeptide comprising a single amino acid substitution in a helix of the HIV envelope glycoprotein polypeptide, wherein the helix is selected from the group consisting of the N36 helix and the C34 helix, wherein said single amino acid substitution increases the ability of said polypeptide to bind neutralizing antibodies,

wherein the single amino acid substitution is selected from the group consisting of V551[*], Q553[*], and Q655[*], where [*] represents any amino acid other than Q or N, and wherein the numbering of the substituted amino acid is with reference to the amino acid sequence set forth in SEQ ID NO: 16.

2. The formulation of claim 1 , comprising an excipient, carrier or adjuvant.

3. The formulation of claim 1 , wherein the single amino acid substitution is V551[*], where [*] represents any amino acid other than Q or N.

4. The formulation of claim 1 , wherein the single amino acid substitution is Q553[*], where [*] represents any amino acid other than Q or N.

5. The formulation of claim 1 , wherein the single amino acid substitution is Q655[*], where [*] represents any amino acid other than Q or N.

6. The formulation of claim 5 , wherein the single amino acid substitution is Q655R.

7. The formulation of claim 5 , wherein the polypeptide comprises the sequence set forth in SEQ ID NO: 16.

8. The formulation of claim 3 , comprising an excipient, a carrier or an adjuvant.

9. The formulation of claim 4 , comprising an excipient, a carrier or an adjuvant.

10. The formulation of claim 5 , comprising an excipient, a carrier or an adjuvant.

11. The formulation of claim 6 , comprising an excipient, a carrier or an adjuvant.

12. The formulation of claim 7 , comprising an excipient, a carrier or an adjuvant.